Ekso Bionics Holdings Inc (NASDAQ:EKSO)’s stock price traded up 7% on Friday . The stock traded as high as $0.52 and last traded at $0.52, 111,409 shares changed hands during mid-day trading. A decline of 74% from the average session volume of 436,034 shares. The stock had previously closed at $0.49.
Several equities analysts recently weighed in on the stock. ValuEngine downgraded shares of Ekso Bionics from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Aegis reiterated a “buy” rating and issued a $2.90 price target on shares of Ekso Bionics in a report on Thursday, August 8th. Finally, Cantor Fitzgerald assumed coverage on shares of Ekso Bionics in a report on Friday, September 6th. They issued an “overweight” rating and a $1.00 price target on the stock.
The business’s 50 day moving average is $0.59 and its 200-day moving average is $1.35. The stock has a market cap of $37.70 million, a price-to-earnings ratio of -1.19 and a beta of 1.56. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.97 and a current ratio of 2.37.
Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.04) earnings per share (EPS) for the quarter. Ekso Bionics had a negative net margin of 162.93% and a negative return on equity of 454.48%. The company had revenue of $3.26 million during the quarter. Sell-side analysts anticipate that Ekso Bionics Holdings Inc will post -0.26 EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN lifted its holdings in Ekso Bionics by 4,401.9% in the 2nd quarter. Wells Fargo & Company MN now owns 49,521 shares of the company’s stock valued at $63,000 after purchasing an additional 48,421 shares in the last quarter. CVI Holdings LLC purchased a new position in Ekso Bionics in the 2nd quarter valued at $494,000. BlackRock Inc. lifted its holdings in Ekso Bionics by 123.2% in the 2nd quarter. BlackRock Inc. now owns 813,996 shares of the company’s stock valued at $1,035,000 after purchasing an additional 449,348 shares in the last quarter. Wasatch Advisors Inc. purchased a new position in Ekso Bionics in the 2nd quarter valued at $2,398,000. Finally, Vanguard Group Inc. lifted its holdings in Ekso Bionics by 41.2% in the 2nd quarter. Vanguard Group Inc. now owns 2,085,186 shares of the company’s stock valued at $2,648,000 after purchasing an additional 608,759 shares in the last quarter. Institutional investors own 36.44% of the company’s stock.
Ekso Bionics Company Profile (NASDAQ:EKSO)
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke.
Recommended Story: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.